Pyxis Oncology, Inc. (PYXS)
Pyxis Oncology develops experimental cancer drugs, led by an antibody drug conjugate for head and neck squamous cell carcinoma. It last closed at $1.81 on Nov 20, up 7.74% on the day. The next earnings report for PYXS is expected around Mon, Mar 22, 2027. For the quarter ended Sep 2026, PYXS reported EPS of -$0.24. Over its last 8 reports the stock moved an average of 7.0% the session after earnings. Over the last 12 months PYXS insiders bought $0 of stock on the open market and sold $107K, according to SEC Form 4 filings.
Key Stats
Last 12 monthsNot reported for this period.
From PYXS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.
- Every upgrade, downgrade and initiation as it happens
- Every price target change, raised or cut
- Consensus rating with the average, high and low targets
- Each firm's full rating history on PYXS
Technical AnalysisPrices may be delayed
The stock sits between its 20 and 50 day averages. It is 19% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 52). The nearest support is the Pivot S1 at $1.68, and the nearest resistance the Pivot at $1.83.
| RSI (14) | 51.91 | Middle of its range | Neutral |
| MACD | -0.13 | Above its signal line | Bullish |
| Stochastic | 50.2 | Middle of its range | Neutral |
| ADX (14) | 35.8 | Trending up | |
| Williams %R | -27.7 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 100.9 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +9.0% | Change over 10 sessions | Bullish |
| ATR (14) | $0.17 | Typical daily range, 9.6% of price |
| RSI (14) | 43.81 | Middle of its range | Neutral |
| MACD | -0.18 | Below its signal line | Bearish |
| Stochastic | 8.6 | Near the bottom of its range | Oversold |
| ADX (14) | 18.5 | No clear trend | |
| Williams %R | -83.3 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -95.9 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −43.6% | Change over 10 sessions | Bearish |
| ATR (14) | $0.59 | Typical daily range, 32.4% of price |
What happened before
See how PYXS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How PYXS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options FlowPrices may be delayed
90DNo whale options trades in PYXS in the last 90 days.
PYXS Institutional Ownership
Full report →- ▲64 buying vs 32 selling
- ▲Held by funds +38.2 pts
- ▲Funds holding +25
- ▲Superinvestors: 3 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 101 | 76 | +32.9% |
| In funds' top 10 | 4 | 2 | +100.0% |
| Held by funds | 66.7% | 28.6% | +38.2 pts |
| New / increased | 38 / 26 | 9 / 24 | +93.9% |
| Reduced / sold out | 19 / 13 | 24 / 10 | −5.9% |
| Put/call ratio | 0.00 | 0.00 | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
PYXS Insider Trading
All filings →| Trade date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 30 | Jakob DupontDirector | Sale plan | 35,000 | $3.06 | $107K |
| Apr 21, 2025 | Rachel HumphreyDirector | Sale plan | 15,496 | $1.02 | $16K |
| Nov 26, 2024 | Pamela Ann ConnealyCFO & COO | Buy | 88,850 | $1.96 | $174K |
From SEC Form 4 filings by PYXS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PYXS is in one of them and how their past PYXS trades turned out.
PYXS News Tone and PricePrices may be delayed
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered PYXS in an article yet. Here's the latest on the wider market.
- Pyxis Oncology to Host Live Webcast on Updated MICVO Phase 1 Monotherapy Data Demonstrating Durable Response in 2L+ R/M HNSCC Following Late-Breaking Oral Presentation at EORTC-NCI-AACR Symposium
- Pyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO)
About Pyxis Oncology
Pyxis Oncology is a cancer drug developer based in Boston, Massachusetts. Its lead product candidate, micvotabart pelidotin, is an experimental antibody drug conjugate that targets a protein found in the tissue surrounding tumors rather than on cancer cells themselves. The company is focused on head and neck squamous cell carcinoma and is testing the drug alone and together with Keytruda, an immunotherapy made by Merck. The drug is still in clinical testing and is not approved for sale, and it is aimed at patients with solid tumors.
- Headquarters
- Boston, MA




